Learning Objectives:


  1. Review veno-occlusive disease (VOD) in allogeneic stem cell transplantation (allo-SCT)
  2. Discuss inotuzumab ozogamicin (INO) use in B-ALL
  3. Report retrospective outcomes of patients treated with INO and allo-SCT at University of Chicago



  1. Review the evidence for immunotherapy in advanced non-small cell lung cancer (NSCLC)
  2. Examine recent data examining the issue of optimal immunotherapy duration for advanced NSCLC
  3.  Discuss potential biomarkers that may assist with treatment duration decisions


Session date: 
08/05/2021 - 12:00pm to 1:00pm CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Kirk Cahill, MD & James Dolezal, MD